Find Suppliers (API/FDF)
Services
Excipients
Developments
News
Blog
Market Place
Login
Market Place

IDE196

Synopsis, Chemistry

Synopsis
Chemistry

DEVELOPMENTS

17 Drug(s) in Development

17 Drug(s) in Development

DIGITAL CONTENT

10 News

10 News

Synopsis Chemistry

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

Drugs in Development News

News

Full Screen View

IDEAYA's Darovasertib Uveal Melanoma Data in ASCO Oral Session

https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-asco-2024-oral-presentation-for-darovasertib-in-neoadjuvant-uveal-melanoma-phase-2-investigator-sponsored-study-302125242.html

PR NEWSWIRE

24 Apr 2024

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023

https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2023-for-phase-2-clinical-data-update-for-darovasertib-and-crizotinib-combination-in-metastatic-uveal-melanoma-301958315.html

PR NEWSWIRE

17 Oct 2023

IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib

https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination-in-gnaq11-metastatic-cutaneous-melanoma-301956860.html

PR NEWSWIRE

16 Oct 2023

IDEAYA Announces First-Patient-In for Phase 2 Evaluating Darovasertib

https://media.ideayabio.com/2023-08-16-IDEAYA-Announces-First-Patient-In-for-Company-Sponsored-Phase-2-Clinical-Trial-Evaluating-Darovasertib-in-Neo-Adjuvant-Uveal-Melanoma

PRESS RELEASE

16 Aug 2023

IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1

https://media.ideayabio.com/2023-06-22-IDEAYA-Announces-First-Reported-Case-of-Uveal-Melanoma-Patient-Spared-Enucleation-in-Phase-1-Neoadjuvant-IST-with-Darovasertib-Monotherapy

PRESS RELEASE

22 Jun 2023

IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer

https://media.ideayabio.com/2023-05-16-IDEAYA-Expands-Clinical-Trial-Collaboration-and-Supply-Agreements-with-Pfizer-to-Support-Registrational-Trial-Evaluating-Darovasertib-and-Crizotinib-Combination-in-First-Line-Metastatic-Uveal-Melanoma

PRESS RELEASE

16 May 2023

IDEAYA Receives Fast Track Designation for Darovasertib with Crizotinib

https://www.prnewswire.com/news-releases/ideaya-biosciences-receives-fast-track-designation-for-darovasertib-combination-therapy-with-crizotinib-for-the-treatment-of-metastatic-uveal-melanoma-301692961.html

PRNEWSWIRE

05 Dec 2022

Ideaya reports positive Phase II data for MUM combination therapy

https://www.clinicaltrialsarena.com/news/ideaya-uveal-melanoma-trial/

CLINICALTRIALSARENA

12 Sep 2022

IDEAYA Announces 1st Patient in for PI Trial Evaluate Darovasertib Monotherapy

https://www.prnewswire.com/news-releases/ideaya-announces-first-patient-in-for-phase-i-clinical-trial-to-evaluate-darovasertib-monotherapy-in-neoadjuvant-uveal-melanoma-301617421.html

PRNEWSWIRE

06 Sep 2022

IDEAYA, Pfizer Expand Trial Collaboration for Darovasertib and Crizotinib

https://www.prnewswire.com/news-releases/ideaya-and-pfizer-expand-clinical-trial-collaboration-and-supply-agreements-for-evaluation-of-darovasertib-and-crizotinib-combination-in-metastatic-uveal-melanoma-and-additional-cmet-driven-tumors-301501338.html

PRNEWSWIRE

14 Mar 2022